Sei Investments CO Immuno Gen, Inc. Transaction History

Sei Investments CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $2.05 Million - $4.93 Million	-164,596 Reduced 84.97%	29,106 $862,000
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $17,795 - $25,095	1,263 Added 0.66%	193,702 $3.07 Million
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $552,442 - $2.95 Million	147,318 Added 326.5%	192,439 $3.63 Million
Q1 2023 May 12, 2023	BUY	$3.67 - $4.92 $165,594 - $221,995	45,121 New	45,121 $173,000
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $972 - $1,782	-540 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $1,301 - $3,191	540 New	540 $1,000
Q3 2018 Nov 08, 2018	SELL	$8.6 - $11.26 $10,320 - $13,512	-1,200 Closed	0 $0
Q2 2018 Aug 03, 2018	SELL	$9.52 - $12.15 $828 - $1,057	-87 Reduced 6.76%	1,200 $12,000
Q1 2018 May 11, 2018	SELL	$6.7 - $12.95 $361 - $699	-54 Reduced 4.03%	1,287 $14,000
Q4 2017 Feb 08, 2018	BUY	$5.07 - $7.92 $233 - $364	46 Added 3.55%	1,341 $9,000
Q3 2017 Nov 06, 2017	BUY	$5.4 - $8.47 $6,993 - $10,968	1,295	1,295 $10,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.